Grant Avenue Capital, a middle market healthcare-focused private equity firm, has launched Helios Clinical Research, a new integrated clinical site organisation that partners with patients, physicians, and biopharma sponsors to optimise clinical research.Â
Grant Avenue Capital (Grant Avenue), a middle market healthcare-focused private equity firm, has launched Helios Clinical Research (Helios), a new integrated clinical site organisation that partners with patients, physicians, and biopharma sponsors to optimise clinical research.
Helios operates 20 integrated clinical research sites that specialise in vaccines, metabolic, urology, orthopaedics, gastroenterology, dermatology, oncology, and broader general medicine across four states, and expects to strategically expand its footprint throughout the US over time.
Helios’s sites support patients by engaging, educating, and providing them with a quality setting to participate in clinical research as a care option, as well as physicians by simplifying the clinical research process to enable them to focus on optimal patient care and data collection. In partnership with biopharma sponsors, Helios expedites the drug approval process, enhancing key delivery components such as study startup, patient recruiting and engagement, and regulatory and quality compliance.
